Atray co-founded Coral after finishing his graduate work in 2018 with a mission of understanding and reducing variability in therapeutic response for all patients. In his role, he works with a diverse team and key external stakeholders in the healthcare system. In Aviv Regev’s lab at the Broad Institute, he focused on developing novel methods for high throughput genetic screening. In 2016, he led a team to develop Perturb-seq, a technology which allows genetically encoded perturbations (like CRISPR edits) to be screened using single cell RNA-seq. Atray also developed new methods to enable large combinatorial screens such as Shuffle-seq. He translated the big data skills learned through these projects during a brief externship at Apple’s Applied Machine Learning division. Atray received an B.S.E. in Mechanical and Aerospace Engineering from Princeton University in 2012 and his Ph.D. in Health Sciences and Technology from MIT in 2018.
AI and Data Sciences Showcase:
Coral Genomics is developing massive patient-centric datasets for the future od pharmacogenomics. Its diverse programs range from immunotherapy to expanding the accuracy of traditional PGx assays as more whole genome information becomes available.
Got Diversity? PolyPGx For Population Sequencing Efforts
The PMWC 2020 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.